103 related articles for article (PubMed ID: 20189243)
1. The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity.
Karve S; Bandekar A; Ali MR; Sofou S
Biomaterials; 2010 May; 31(15):4409-16. PubMed ID: 20189243
[TBL] [Abstract][Full Text] [Related]
2. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
[TBL] [Abstract][Full Text] [Related]
3. The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy.
Karve S; Alaouie A; Zhou Y; Rotolo J; Sofou S
Biomaterials; 2009 Oct; 30(30):6055-64. PubMed ID: 19665223
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin.
Bandekar A; Karve S; Chang MY; Mu Q; Rotolo J; Sofou S
Biomaterials; 2012 Jun; 33(17):4345-52. PubMed ID: 22429980
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
Mamasheva E; O'Donnell C; Bandekar A; Sofou S
Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
[TBL] [Abstract][Full Text] [Related]
6. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
Obata Y; Tajima S; Takeoka S
J Control Release; 2010 Mar; 142(2):267-76. PubMed ID: 19861141
[TBL] [Abstract][Full Text] [Related]
8. Active loading and tunable release of doxorubicin from block copolymer vesicles.
Choucair A; Soo PL; Eisenberg A
Langmuir; 2005 Sep; 21(20):9308-13. PubMed ID: 16171366
[TBL] [Abstract][Full Text] [Related]
9. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker.
Lavignac N; Nicholls JL; Ferruti P; Duncan R
Macromol Biosci; 2009 May; 9(5):480-7. PubMed ID: 19016501
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous domains and membrane permeability in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch.
Karve S; Bajagur Kempegowda G; Sofou S
Langmuir; 2008 Jun; 24(11):5679-88. PubMed ID: 18471003
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
12. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting.
Munnier E; Cohen-Jonathan S; Linassier C; Douziech-Eyrolles L; Marchais H; Soucé M; Hervé K; Dubois P; Chourpa I
Int J Pharm; 2008 Nov; 363(1-2):170-6. PubMed ID: 18687392
[TBL] [Abstract][Full Text] [Related]
13. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
14. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes.
Zhang X; Meng L; Lu Q; Fei Z; Dyson PJ
Biomaterials; 2009 Oct; 30(30):6041-7. PubMed ID: 19643474
[TBL] [Abstract][Full Text] [Related]
16. Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents.
Chen T; McIntosh D; He Y; Kim J; Tirrell DA; Scherrer P; Fenske DB; Sandhu AP; Cullis PR
Mol Membr Biol; 2004; 21(6):385-93. PubMed ID: 15764368
[TBL] [Abstract][Full Text] [Related]
17. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
18. Cell-specific delivery of a chemotherapeutic to lung cancer cells.
Zhou X; Chang YC; Oyama T; McGuire MJ; Brown KC
J Am Chem Soc; 2004 Dec; 126(48):15656-7. PubMed ID: 15571383
[TBL] [Abstract][Full Text] [Related]
19. Nano-scaled pH-responsive polymeric vesicles for intracellular release of doxorubicin.
Huang WC; Chiang WH; Huang YF; Lin SC; Shih ZF; Chern CS; Chiang CS; Chiu HC
J Drug Target; 2011 Dec; 19(10):944-53. PubMed ID: 22050402
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
